Lastacaft   (U.S.N.L.M.)
Dosing 1 drop daily
Chem Specs alcaftadine 0.25%
Quantities 3 mL
Cost 290.14/3ml
Class H1, H2, H4 receptor antagonist¹
Action Competitive H1 receptor inhibitor.  Mast cell stabilizer. Decreased
chemotaxis and inhibition of eosinophil activation has also been demonstrated.
Usage Indicated for the treatment of itching associated with allergic conjunctivitis.
BAK may be absorbed in soft contact lenses.
Contact lenses may be inserted 10 minutes after administration.
Contraindications Hypersensitivity to any component of the product..
Pediatric use Safety and efficacy not established for patients under 2 years of age.
Pregnancy Category B. No maternal or embryofetal toxicity at clinically relevant doses
in animal studies.
BAK .005%
    N.L.M. DailyMed page for Lastacaft          PDR page for Lastacaft
¹ Gallois-Bernos & Thurmond

One study found less itch and better chemosis relief with alcaftadine than olopatadine.
Ackerman, D’Ambrosio, Greiner, Villanueva, Ciolino, and Hollander